Skip to main content
Top
Published in: Annals of Hematology 9/2012

01-09-2012 | Original Article

Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?

GIMEMA and EORTC Quality of Life Group

Authors: Fabio Efficace, Massimo Breccia, Susanne Saussele, Ute Kossak-Roth, Annarita Cardoni, Giovanni Caocci, Weichu Chie, Adel Naeem, Ourania Nicolatou-Galitis, Kim Cocks, Marco Vignetti, Michele Baccarani, Franco Mandelli, Mirjam Sprangers

Published in: Annals of Hematology | Issue 9/2012

Login to get access

Abstract

The objective of this study was to investigate the health-related quality of life (HRQOL) aspects valued the most by patients with chronic myeloid leukemia (CML) receiving targeted therapies (TT), and to compare their perception with that of health-care professionals’ (HCPs). Semi-structured interviews were conducted with 137 CML patients receiving TT from five different countries. An additional sample of 99 CML patients, completing an online interview, was considered for supportive analyses. A sample of 59 HCPs from 12 countries also participated in the study. Patients and HCPs were asked to rate and rank the importance of a predefined list of 74 HRQOL aspects of potential relevance for CML patients. Patients and HCPs agreed that the following five aspects are most important: fatigue, muscle cramps, swelling, worries, and uncertainty about health condition in the future, and importance of social support in coping with the disease. However, the difference in rankings between the two groups was substantial with respect to other HRQOL aspects investigated. Patients valued some issues related to symptoms much higher than HCPs, thus suggesting that a better symptom management could be the crucial aspects to improve HRQOL of CML patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kris MG, Benowitz SI, Adams S et al (2010) Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 28(36):5327–5347PubMedCrossRef Kris MG, Benowitz SI, Adams S et al (2010) Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 28(36):5327–5347PubMedCrossRef
2.
go back to reference Cortes JE, Jones D, O'Brien S et al (2010) Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28(3):398–404PubMedCrossRef Cortes JE, Jones D, O'Brien S et al (2010) Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 28(3):398–404PubMedCrossRef
3.
go back to reference Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251–2259PubMedCrossRef Saglio G, Kim DW, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362(24):2251–2259PubMedCrossRef
4.
go back to reference Kantarjian HM, Giles FJ, Bhalla KN et al (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117(4):1141–1145PubMedCrossRef Kantarjian HM, Giles FJ, Bhalla KN et al (2011) Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 117(4):1141–1145PubMedCrossRef
5.
go back to reference Efficace F, Cocks K, Breccia M et al (2012) Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 81(2):123–135PubMedCrossRef Efficace F, Cocks K, Breccia M et al (2012) Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 81(2):123–135PubMedCrossRef
7.
go back to reference de Haes JC (1988) Quality of life: conceptual and theoretical considerations. In: Watson M, Greer S, Thomas C (eds) Psychosocial oncology. Pergamon Press, Oxford, pp 61–70 de Haes JC (1988) Quality of life: conceptual and theoretical considerations. In: Watson M, Greer S, Thomas C (eds) Psychosocial oncology. Pergamon Press, Oxford, pp 61–70
9.
go back to reference Efficace F, Baccarani M, Breccia M et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118(17):4554–4560PubMedCrossRef Efficace F, Baccarani M, Breccia M et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118(17):4554–4560PubMedCrossRef
10.
go back to reference Johnson C, Aaronson N, Blazeby JM et al (2011) EORTC guidelines for developing questionnaire modules. EORTC Publication, Brussels Johnson C, Aaronson N, Blazeby JM et al (2011) EORTC guidelines for developing questionnaire modules. EORTC Publication, Brussels
11.
go back to reference Basch E, Bennett A, Pietanza MC (2011) Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 103(24):1808–1810PubMedCrossRef Basch E, Bennett A, Pietanza MC (2011) Use of patient-reported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 103(24):1808–1810PubMedCrossRef
12.
go back to reference Harris K, Chow E, Zhang L et al (2009) Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. Eur J Cancer 45(14):2510–2518PubMedCrossRef Harris K, Chow E, Zhang L et al (2009) Patients' and health care professionals' evaluation of health-related quality of life issues in bone metastases. Eur J Cancer 45(14):2510–2518PubMedCrossRef
14.
go back to reference Laugsand E, Sprangers M, Bjordal K et al (2010) Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcome 8:104CrossRef Laugsand E, Sprangers M, Bjordal K et al (2010) Health care providers underestimate symptom intensities of cancer patients: a multicenter European study. Health Qual Life Outcome 8:104CrossRef
15.
go back to reference Edelman EJ, Gordon K, Justice AC (2011) Patient and provider-reported symptoms in the post-cART era. AIDS Behav 15(4):853–861PubMedCrossRef Edelman EJ, Gordon K, Justice AC (2011) Patient and provider-reported symptoms in the post-cART era. AIDS Behav 15(4):853–861PubMedCrossRef
16.
go back to reference Nazha A, Williams LA, Kantarjian H et al (2011) Fatigue in chronic myelogenous leukemia patients (pts) treated with tyrosine kinase inhibitors (TKI). Blood (ASH Annual Meeting Abstracts) 118, Abstract 3785 Nazha A, Williams LA, Kantarjian H et al (2011) Fatigue in chronic myelogenous leukemia patients (pts) treated with tyrosine kinase inhibitors (TKI). Blood (ASH Annual Meeting Abstracts) 118, Abstract 3785
17.
go back to reference Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381–2388PubMedCrossRef Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28(14):2381–2388PubMedCrossRef
18.
go back to reference Pinilla-Ibarz J, Cortes J, Mauro MJ (2011) Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer 117(4):688–697PubMedCrossRef Pinilla-Ibarz J, Cortes J, Mauro MJ (2011) Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer 117(4):688–697PubMedCrossRef
19.
go back to reference Savage DG, Szydlo RM, Goldman (1997) Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 96:111–116PubMedCrossRef Savage DG, Szydlo RM, Goldman (1997) Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 96:111–116PubMedCrossRef
20.
go back to reference Sneeuw KC, Sprangers MA, Aaronson NK (2002) The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. J Clin Epidemiol 55(11):1130–1143PubMedCrossRef Sneeuw KC, Sprangers MA, Aaronson NK (2002) The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease. J Clin Epidemiol 55(11):1130–1143PubMedCrossRef
21.
go back to reference Petersen MA, Larsen H, Pedersen L et al (2006) Assessing health-related quality of life in palliative care: comparing patient and physician assessments. Eur J Cancer 42(8):1159–1166PubMedCrossRef Petersen MA, Larsen H, Pedersen L et al (2006) Assessing health-related quality of life in palliative care: comparing patient and physician assessments. Eur J Cancer 42(8):1159–1166PubMedCrossRef
22.
go back to reference Gambacorti-Passerini C, Antolini L, Mahon F-X et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103(7):553–561PubMedCrossRef Gambacorti-Passerini C, Antolini L, Mahon F-X et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103(7):553–561PubMedCrossRef
23.
go back to reference Efficace F, Breccia M, Saussele S, et al (2011) International development of an EORTC measure to assess patient-reported quality of life (QoL) and symptoms in chronic myeloid leukemia (CML). Blood (ASH Annual Meeting Abstracts) 118: Abstract 3132 Efficace F, Breccia M, Saussele S, et al (2011) International development of an EORTC measure to assess patient-reported quality of life (QoL) and symptoms in chronic myeloid leukemia (CML). Blood (ASH Annual Meeting Abstracts) 118: Abstract 3132
Metadata
Title
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?
GIMEMA and EORTC Quality of Life Group
Authors
Fabio Efficace
Massimo Breccia
Susanne Saussele
Ute Kossak-Roth
Annarita Cardoni
Giovanni Caocci
Weichu Chie
Adel Naeem
Ourania Nicolatou-Galitis
Kim Cocks
Marco Vignetti
Michele Baccarani
Franco Mandelli
Mirjam Sprangers
Publication date
01-09-2012
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 9/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-012-1458-6

Other articles of this Issue 9/2012

Annals of Hematology 9/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.